Massimo Tortarolo

List of Publications by Year
in descending order

38 papers	1,904 citations	257357 24 h-index	330025 37 g-index
38 all docs	38 docs citations	38 times ranked	2741 citing authors

#	Article	IF	Citations
1	Mutant Copper-Zinc Superoxide Dismutase (SOD1) Induces Protein Secretion Pathway Alterations and Exosome Release in Astrocytes. Journal of Biological Chemistry, 2013, 288, 15699-15711.	1.6	216
2	Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. Journal of Neurochemistry, 2008, 79, 737-746.	2.1	173
3	Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Molecular and Cellular Neurosciences, 2003, 23, 180-192.	1.0	155
4	Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosisâ€. Human Molecular Genetics, 2009, 18, 82-96.	1.4	146
5	Glutamate AMPA receptors change in motor neurons of SOD1G93A transgenic mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amytrophic lateral sclerosis-like disease. Journal of Neuroscience Research, 2006, 83, 134-146.	1.3	104
6	Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Molecular and Cellular Neurosciences, 2006, 31, 218-231.	1.0	92
7	Lack of apoptosis in mice with ALS. Nature Medicine, 1999, 5, 966-967.	15.2	90
8	Activated p38MAPK Is a Novel Component of the Intracellular Inclusions Found in Human Amyotrophic Lateral Sclerosis and Mutant SOD1 Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2004, 63, 113-119.	0.9	81
9	Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse. Biochemical and Biophysical Research Communications, 2007, 353, 719-725.	1.0	72
10	Glutamate release in human cerebral cortex and its modulation by 5â€hydroxtryptamine acting at h 5â€HT 1D receptors. British Journal of Pharmacology, 1998, 123, 45-50.	2.7	61
11	Expression of SOD1 G93A or wildâ€type SOD1 in primary cultures of astrocytes downâ€regulates the glutamate transporter GLTâ€1: lack of involvement of oxidative stress. Journal of Neurochemistry, 2004, 88, 481-493.	2.1	57
12	New Insights on the Mechanisms of Disease Course Variability in ALS from Mutant SOD1 Mouse Models. Brain Pathology, 2016, 26, 237-247.	2.1	56
13	Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNFÎ±. Mediators of Inflammation, 2017, 2017, 1-16.	1.4	45
14	Inter- and Intracellular Signaling in Amyotrophic Lateral Sclerosis: Role of p38 Mitogen-Activated Protein Kinase. Neurodegenerative Diseases, 2005, 2, 128-134.	0.8	42
15	Targeting Extracellular Cyclophilin A Reduces Neuroinflammation and Extends Survival in a Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2017, 37, 1413-1427.	1.7	42
16	Lack of TNFâ€alpha receptor type 2 protects motor neurons in a cellular model of amyotrophic lateral sclerosis and in mutant SOD1 mice but does not affect disease progression. Journal of Neurochemistry, 2015, 135, 109-124.	2.1	33
17	RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue. Journal of Neuroinflammation, 2018, 15, 65.	3.1	33
18	Specific Induction of Akt3 in Spinal Cord Motor Neurons is Neuroprotective in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2014, 49, 136-148.	1.9	32

#	Article	IF	Citations
19	Differential Expression of S100Î² and Glial Fibrillary Acidic Protein in the Hippocampus after Kainic Acid-Induced Lesions and Mossy Fiber Sprouting in Adult Rat. Experimental Neurology, 2000, 161, 317-329.	2.0	31
20	Unraveling the Complexity of Amyotrophic Lateral Sclerosis: Recent Advances from the Transgenic Mutant SOD1 Mice. CNS and Neurological Disorders - Drug Targets, 2010, 9, 491-503.	0.8	31
21	Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 340-344.	2.3	30
22	Biocompatible fluorescent nanoparticles forin vivostem cell tracking. Nanotechnology, 2013, 24, 245603.	1.3	29
23	Multiple intracerebroventricular injections of human umbilical cord mesenchymal stem cells delay motor neurons loss but not disease progression of SOD1G93A mice. Stem Cell Research, 2017, 25, 166-178.	0.3	29
24	Expression of glutamate receptor subtypes in the spinal cord of control andmnd mice, a model of motor neuron disorder. Journal of Neuroscience Research, 2002, 70, 553-560.	1.3	25
25	Lentiviral vectors carrying enhancer elements of Hb9 promoter drive selective transgene expression in mouse spinal cord motor neurons. Journal of Neuroscience Methods, 2012, 205, 139-147.	1.3	23
26	Erythropoietin does not preserve motor neurons in a mouse model of familial ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 31-35.	2.3	21
27	Human SOD1-G93A Specific Distribution Evidenced in Murine Brain of a Transgenic Model for Amyotrophic Lateral Sclerosis by MALDI Imaging Mass Spectrometry. Journal of Proteome Research, 2014, 13, 1800-1809.	1.8	21
28	Glial activation and TNFR-I upregulation precedes motor dysfunction in the spinal cord of mnd mice. Cytokine, 2004, 25, 127-135.	1.4	20
29	Altered Metabolic Profiles Associate with Toxicity in SOD1G93A Astrocyte-Neuron Co-Cultures. Scientific Reports, 2017, 7, 50.	1.6	20
30	Longitudinal tracking of triple labeled umbilical cord derived mesenchymal stromal cells in a mouse model of Amyotrophic Lateral Sclerosis. Stem Cell Research, 2015, 15, 243-253.	0.3	19
31	Spinal Cord Metabolic Signatures in Models of Fast- and Slow-Progressing SOD1G93A Amyotrophic Lateral Sclerosis. Frontiers in Neuroscience, 2019, 13, 1276.	1.4	14
32	A Mouse Model of Familial ALS Has Increased CNS Levels of Endogenous Ubiquinol9/10 and Does Not Benefit from Exogenous Administration of Ubiquinol10. PLoS ONE, 2013, 8, e69540.	1.1	14
33	Kif1B? isoform is enriched in motor neurons but does not change in a mouse model of amyotrophic lateral sclerosis. Journal of Neuroscience Research, 2003, 71, 732-739.	1.3	12
34	Targeting Stress Activated Protein Kinases, JNK and p38, as New Therapeutic Approach for Neurodegenerative Diseases. Central Nervous System Agents in Medicinal Chemistry, 2006, 6, 109-117.	0.5	12
35	A Novel HGF/SF Receptor (MET) Agonist Transiently Delays the Disease Progression in an Amyotrophic Lateral Sclerosis Mouse Model by Promoting Neuronal Survival and Dampening the Immune Dysregulation. International Journal of Molecular Sciences, 2020, 21, 8542.	1.8	8
36	The p97â€Nploc4 ATPase complex plays a role in muscle atrophy during cancer and amyotrophic lateral sclerosis. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 2225-2241.	2.9	7

#	Article	IF	Citations
37	Presymptomatically applied AMPA receptor antagonist prevents calcium increase in vulnerable type of motor axon terminals of mice modeling amyotrophic lateral sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1739-1748.	1.8	5
38	Translational Research in ALS. , 2008, , 267-310.		3